There are currently several promising MET-TKIs, bispecific antibodies targeting EGFR and MET, and MET-targeting antibody-drug conjugates (ADCs) being investigated in clinical trials for NSCLC patients with MET-deregulation [11,12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.